Phys Ed: 10 Years After an Exercise Study, Benefits Persist
The benefits of exercise may last longer than many of us might expect. (Source: NYT Health)
Source: NYT Health - April 17, 2019 Category: Consumer Health News Authors: GRETCHEN REYNOLDS Tags: Exercise Diabetes Insulin Research Weight Source Type: news

Medical News Today: Can purple corn reduce inflammation, diabetes?
Researchers bred a number of new varieties of purple corn and used a mouse cell model to study how these can reduce inflammation and insulin resistance. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 17, 2019 Category: Consumer Health News Tags: Diabetes Source Type: news

Medical News Today: Diabetes: Can cheese control blood sugar?
Many people with diabetes eat low-fat cheese. However, researchers have shown that both low-fat and regular cheese may be good for regulating insulin. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 16, 2019 Category: Consumer Health News Tags: Diabetes Source Type: news

Back to the Future: Relearning How to Use Human Insulin Back to the Future: Relearning How to Use Human Insulin
Jay Shubrook and Anne Peters describe best-practice strategies for using human insulin in patients who cannot afford analogues.Medscape Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care Expert Interview Source Type: news

Study: Phenols in purple corn fight diabetes, obesity, inflammation in mouse cells
(University of Illinois at Urbana-Champaign) Scientists at the University of Illinois developed new purple corn hybrids with differing combinations of phenols in the pericarp that fight obesity, inflammation and insulin resistance, a new study in mice suggests. The pericarp also provides the food industry with a new source of colorants and farmers with a new value added product for their crops. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2019 Category: International Medicine & Public Health Source Type: news

A Diabetes Drug Called Invokana May Prevent or Slow Kidney Disease, a New Study Says
A drug that’s used to help control blood sugar in people with diabetes has now been shown to help prevent or slow kidney disease, which causes millions of deaths each year and requires hundreds of thousands of people to use dialysis to stay alive. Doctors say it’s hard to overstate the importance of this study, and what it means for curbing this problem, which is growing because of the obesity epidemic. The study tested Janssen Pharmaceuticals’ drug Invokana. Results were discussed Sunday at a medical meeting in Australia and published by the New England Journal of Medicine. About 30 million Americans and...
Source: TIME: Health - April 15, 2019 Category: Consumer Health News Authors: MARILYNN MARCHIONE / AP Tags: Uncategorized medicine onetime overnight Source Type: news

The New Old Age: A New Rx for Diabetes: Lighten Up
In older patients, rigorous lowering of blood sugar may offer few benefits and pose unexpected risks. (Source: NYT Health)
Source: NYT Health - April 12, 2019 Category: Consumer Health News Authors: PAULA SPAN Tags: Diabetes Elderly Hypoglycemia Insulin University of California, San Francisco blood sugar Source Type: news

Can You Recognize Insulin Resistance in Children? Can You Recognize Insulin Resistance in Children?
While hard to measure, it appears that rates of insulin resistance in children are rising. What can we do about it?CHOP Expert Commentary (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 12, 2019 Category: Consumer Health News Tags: Pediatrics Expert Interview Source Type: news

House Lawmakers Grill Drugmakers, PBMs on Insulin Cost House Lawmakers Grill Drugmakers, PBMs on Insulin Cost
Ahead of a Wednesday hearing, Sanofi announced a plan to offer insulin for $99 a month. Cigna also recently made a similar price-cutting move amid congressional inquiries into insulin costs.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 11, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Blame Game on Insulin Costs Leaves Patients Behind
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives. (Source: WebMD Health)
Source: WebMD Health - April 11, 2019 Category: Consumer Health News Source Type: news

Insulin makers grilled on price surge, as diabetics struggle to afford life-saving meds
Pressure from Congress appears to be spurring the pharmaceutical industry to lower prescription drug prices for some patients. One of the main producers of insulin, Sanofi, said it will cap the cost of the life-saving drug for diabetics. Some could save thousands of dollars a year. Anna Werner reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - April 11, 2019 Category: Consumer Health News Source Type: news

Diabetics rationing insulin amid rising drug prices
Drug industry executives faced tough questions Wednesday from Congress over the rising cost of insulin. It's nearly doubled in the last five years, forcing some diabetics to ration the drug. Anna Werner reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - April 11, 2019 Category: Consumer Health News Source Type: news

Lawmakers in Both Parties Vow to Rein In Insulin Costs
A hearing on Wednesday was one of several signs that Congress was serious about trying to address the cries of distress from constituents unable to afford the medicines they need. (Source: NYT Health)
Source: NYT Health - April 11, 2019 Category: Consumer Health News Authors: ROBERT PEAR Tags: Diabetes Drugs (Pharmaceuticals) Prices (Fares, Fees and Rates) Health Insurance and Managed Care Insulin Source Type: news

"People are dying": Insulin being rationed as drug prices rise
A recent study found one in four patients reported "cost-related underuse" (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - April 11, 2019 Category: Consumer Health News Source Type: news

On rising insulin prices, lawmaker tells pharma execs: 'Your days are numbered'
Lawmakers tensed with frustration, some clenching their jaws, while grilling a panel of pharmacy and pharmaceutical company executives about the soaring cost of insulin during a congressional hearing on Wednesday. The tension could be felt as some executives fidgeted in their chairs while answering lawmakers' questions. (Source: CNN.com - Health)
Source: CNN.com - Health - April 10, 2019 Category: Consumer Health News Source Type: news

Sanofi to cut U.S. insulin costs for some patients to $99 per month
Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication. (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Phys Ed: Sitting for More Than 13 Hours a Day May Sabotage the Benefits of Exercise
People who sat for long periods and took fewer than 4,000 steps a day developed metabolic problems, even if they exercised. (Source: NYT Health)
Source: NYT Health - April 10, 2019 Category: Consumer Health News Authors: GRETCHEN REYNOLDS Tags: Exercise Diabetes Sugar Triglycerides Insulin Heart Weight Source Type: news

Six policy solutions to help patients afford their insulin
Dramatic improvements in how we treat diabetes have transformed the lives of patients, but too many struggle to afford their insulin and other medicines at the pharmacy counter. Due to negotiations, prices for insulin after discounts and rebates have fallen in recent years. But too often, these negotiated discounts and rebates are not shared with patients, resulting in patients with diabetes paying higher out-of-pocket costs for their insulin than their insurer pays.Here are six policy solutions that could directly lower diabetes patients' costs at the pharmacy counter: (Source: The Catalyst)
Source: The Catalyst - April 9, 2019 Category: Pharmaceuticals Tags: Part D Medicare Out of Pocket Costs Let's Talk About Cost Source Type: news

Why Does Medicine Cost So Much? Here ’s How Drug Prices Are Set
From 2007 to 2016, Mylan raised the list price of its EpiPen about 500%, from just under $100 to more than $600. From 2002 to 2013, insulin prices more than tripled. From 2012 to 2019, the average price of AbbVie’s rheumatoid-arthritis drug Humira climbed from $19,000 a year to $60,000 a year—and that’s after rebates. These are dramatic examples of a systemwide problem: prices for brand-name drugs are rising at a rate that far outstrips inflation. What’s behind these rapid price hikes? It’s a simple question with a complicated answer that involves three central entities: drug manufacturers, ph...
Source: TIME: Health - April 9, 2019 Category: Consumer Health News Authors: Laura Entis Tags: Uncategorized medicine Source Type: news

Insulin pumps better for children with type 1 diabetes and autism
A study, published inPediatric Diabetes, reports that insulin pump therapy in autistic children with type 1 diabetes is better for blood glucose control.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - April 9, 2019 Category: Endocrinology Source Type: news

Medical News Today: Diabetes: Could targeting this protein prevent hypoglycemia?
Could targeting the protein neuronostatin prevent or treat dangerous low blood sugar in people with diabetes who use insulin? A new study investigates. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 8, 2019 Category: Consumer Health News Tags: Diabetes Source Type: news

Dietary Insulin Load and Cancer Recurrence in Colon Cancer Dietary Insulin Load and Cancer Recurrence in Colon Cancer
A high-insulinogenic diet may put patients at higher risk for colon cancer recurrence.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 8, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Type 2 diabetes: The tasty sweet treat that can help prevent blood sugar spikes
TYPE 2 diabetes sufferers are advised to cut down on sugar in order to control the condition, but there is one sweet treat that can actually help to improve insulin sensitivity and prevent blood sugar from rising. (Source: Daily Express - Health)
Source: Daily Express - Health - April 6, 2019 Category: Consumer Health News Source Type: news

Insulin signalling causes genome-wide alterations in gene expression
According to a paper, published inCell, after the insulin receptor binds to insulin, it moves to the nucleus where it alters the expression of numerous genes. This mechanism is impaired in insulin-resistant mice and may be a new target for diabetes treatment.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - April 5, 2019 Category: Endocrinology Source Type: news

Schizophrenia Risk and Insulin Resistance Intrinsically Linked Schizophrenia Risk and Insulin Resistance Intrinsically Linked
Schizophrenia patients with insulin resistance show diminished response to antipsychotic medication and may require personalized treatment.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 4, 2019 Category: Psychiatry Tags: Psychiatry News Source Type: news

Under Dr. Gottlieb, CDRH continued bringing innovative devices to market using a total product life-cycle approach. For example, expanded approval of an automated insulin dosing system for people age 7 and up with diabetes and the world ’ s smallest heart valve for newborns.pic.twitter.com/SNokx8QVXW
Under Dr. Gottlieb, CDRH continued bringing innovative devices to market using a total product life-cycle approach. For example, expanded approval of an automated insulin dosing system for people age 7 and up with diabetes and the world’s smallest heart valve for newborns. pic.twitter.com/SNokx8QVXW (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - April 4, 2019 Category: Medical Devices Authors: ( at FDADeviceInfo) Source Type: news

Closed-loop insulin delivery significantly improves glycaemic control
A study, published inThe Lancet Diabetes and Endocrinology, reports that closed-loop insulin delivery for inpatients receiving nutritional support maintains recommended blood glucose levels for longer.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - April 4, 2019 Category: Endocrinology Source Type: news

High Insulin Costs Come Under Fire on Capitol Hill
Title: High Insulin Costs Come Under Fire on Capitol HillCategory: Health NewsCreated: 4/3/2019 12:00:00 AMLast Editorial Review: 4/4/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - April 4, 2019 Category: Endocrinology Source Type: news

New insulin price won't top $25 a month out-of-pocket, Cigna says
Health insurer Cigna is launching a program that will cap out-of-pocket expenses at $25 for a 30-day supply of insulin, the company said Wednesday. Last year, patients paid an average of $41.50 a month out of pocket, including deductibles, copays or coinsurance, for the lifesaving diabetes drug, the company said. (Source: CNN.com - Health)
Source: CNN.com - Health - April 3, 2019 Category: Consumer Health News Source Type: news

High Insulin Costs Come Under Fire on Capitol Hill
WEDNESDAY, April 3, 2019 -- For many Americans, the cost of lifesaving insulin is simply too high, leading as many as one in four to ration the drug, experts testifying before the House Committee on Energy and Commerce said this week. The meeting... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 3, 2019 Category: General Medicine Source Type: news

New Plan Limits Out-of-Pocket Costs for Insulin
The average price of insulin rose from about $234 a month in 2012 to about $450 a month in 2016, according to the Health Cost Institute. (Source: WebMD Health)
Source: WebMD Health - April 3, 2019 Category: Consumer Health News Source Type: news

Cigna lowers insulin price to $25 per month
Under pressure from patients and the FDA, Cigna (NYSE:CI) and Express Scripts said today that they will lower the price of insulin to $25 per month for some patients. Three firms — Eli Lilly, Novo Nordisk and Sanofi — control 90% of the global insulin market and produce all the insulin used in the U.S. Insulin list prices regularly increase by double digits annually, according to the FDA, which attributed the price hikes to a lack of competition. Get the full story on our sister site, Drug Delivery Business. (Source: Mass Device)
Source: Mass Device - April 3, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Diabetes Featured Food & Drug Administration (FDA) News Well Pharma Pharmaceuticals Regulatory/Compliance Cigna Eli Lilly & Co. Express Scripts Novo Nordisk Sanofi Source Type: news

Efficacy and Safety of IDegLira in Older Patients With T2D Efficacy and Safety of IDegLira in Older Patients With T2D
IDegLira is an insulin degludec/liraglutide combination that has been shown to improve glycemic control in type 2 diabetes. Is it a safe and effective option for older patients?Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

US Lawmakers Hone in on PBM Role in Insulin Prices US Lawmakers Hone in on PBM Role in Insulin Prices
A Texas physician-lawmaker pitched an idea at a hearing about having Medicare and Medicaid cover insulin's entire cost. For now, Congress is focused instead on middlemens'part in rising drug prices.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 3, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

New Plan Limits Out-of-Pocket Costs for Insulin
WEDNESDAY, April 3, 2019 -- Out-of-pocket costs for insulin could be restricted to $25 a month for people under a drug benefit plan announced Wednesday by Express Scripts. The average monthly savings for workers whose employers adopt the plan would... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 3, 2019 Category: Pharmaceuticals Source Type: news

The Health 202: A major insurer is announcing insulin savings amid heavy Hill pressure
The hearings are coming. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - April 3, 2019 Category: Consumer Health News Authors: Paige Winfield Cunningham Source Type: news

Cigna launches program to cap out-of-pocket insulin costs at $25/month
Health insurer Cigna Corp on Wednesday launched a program aimed at ensuring some diabetes patients pay no more than $25 for a 30-day supply of insulin in the wake of heightened public scrutiny over soaring prices of the life-saving drug. (Source: Reuters: Health)
Source: Reuters: Health - April 3, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Express Scripts Offers Diabetes Patients a $25 Cap for Monthly Insulin
Drug makers, insurers and pharmacy benefit managers face mounting pressure from Congress and the public to reduce the high list prices of drugs like insulin. (Source: NYT Health)
Source: NYT Health - April 3, 2019 Category: Consumer Health News Authors: KATIE THOMAS Tags: Diabetes Insulin Express Scripts Inc Health Insurance and Managed Care Drugs (Pharmaceuticals) CIGNA Corporation your-feed-science Source Type: news

Cigna ’s Express Scripts PBM To Cap Insulin Costs Amid Drug Price Scrutiny
Cigna and Express Scripts are rolling out a new program to cap out-of-pocket costs for insulin at $25 per 30-day prescriptions. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 3, 2019 Category: Pharmaceuticals Authors: Bruce Japsen, Contributor Source Type: news

Health Highlights: April 3, 2019
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: New Plan Limits Out-of-Pocket Costs for Insulin Out-of-pocket costs for insulin could be restricted to $25 a month for people under a drug... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 3, 2019 Category: General Medicine Source Type: news

FDA Eyes Tailored Approach to Regulating AI-Based Medical Devices
FDA Commissioner Scott Gottlieb is making the most of his final week at the agency. In the month that has passed since Gottlieb rattled the medical device industry with news of his impending resignation, the commissioner has issued 18 public statements pertaining to nearly all corners of the agency's realm, from food, tobacco, and cosmetics to drugs and devices. Friday is Gottlieb's last day on the job. On Tuesday, Gottlieb said the agency will consider a new regulatory framework for reviewing medical devices that use advanced artificial intelligence algorithms. AI has been making headlines in medtech for a whi...
Source: MDDI - April 3, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Software Source Type: news

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency ’ s continued efforts to bring competition to the insulin market to lower prices and expand access
FDA is announcing a public hearing to discuss access to affordable insulin products. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 2, 2019 Category: American Health Source Type: news

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency ’s continued efforts to bring competition to the insulin market to lower prices and expand access
FDA is announcing a public hearing to discuss access to affordable insulin products. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 2, 2019 Category: American Health Source Type: news

The staggering cost of Type 1 diabetes: It's not just about insulin
Public insurance programs paid an average of $967 annually on insulin for people with Type 1 diabetes last year. That’s 33 per cent more than in 2011. But insulin is just a small portion of the staggering costs of managing the condition. (Source: CBC | Health)
Source: CBC | Health - April 2, 2019 Category: Consumer Health News Tags: News/Health Source Type: news

Five key facts about the market for insulins
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released naturally in the body and more effectively managing the disease. The options available today also help meet a wide range of unmet needs, providing patients with the tools necessary to stay adherent and healthy – saving costs throughout the health care system. However, this innovation isn’t enough if patients can’t afford their insulin and other medicines at the pharmacy. (Source: The Catalyst)
Source: The Catalyst - April 1, 2019 Category: Pharmaceuticals Tags: diabetes Out of Pocket Costs Pharmacy Benefit Managers Let's Talk About Cost Source Type: news

German nurse charged with killing 6 of his patients
Munich prosecutors have charged a nurse with murder on allegations he killed six patients in his care with injections of insulin that they did not medically need (Source: ABC News: Health)
Source: ABC News: Health - April 1, 2019 Category: Consumer Health News Tags: Health Source Type: news

Researchers say consuming fish oils is linked to lower insulin-promoted breast cancer risk
(Natural News) Breast cancer is among the most studied diseases, and scientists are hard at work coming up with ways to prevent it. A team of researchers from China explored the effects of omega-3 fatty acids on lowering insulin levels – one of the risk factors for breast cancer. The researchers tested the ability of omega-3... (Source: NaturalNews.com)
Source: NaturalNews.com - March 29, 2019 Category: Consumer Health News Source Type: news

Could Biolinq ’s Patch Change the Game For CGMs?
Biolinq has a plan to redefine continuous glucose monitoring (CGM) and investors are supporting it. The San Diego-based just announced it raised an additional $4.75 million in a series A round to help it get its CGM patch through clinical trials. The latest tranche was led by the JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners. Previously, Biolinq had closed on $10 million in the round – bringing the total financing amount to nearly $15 million. The funding round was no easy task, said Jared Tangney, Biolinq’s CEO. “There have been a lot of investors that h...
Source: MDDI - March 28, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Valeritas inks Israeli distro deal with Tritech Biomed
Valeritas (NSDQ:VLRX) said today that it inked an exclusive distribution deal with Tritech Biomed to commercialize its V-Go wearable insulin delivery device designed for patients with Type 2 diabetes in Israel. Through the deal, the Bridgewater, N.J.-based company said that Tritech Biomed will have rights to promote, market and sell the V-Go system to diabetes clinics and patients in the region. Read the whole story on our sister site, Drug Delivery Business News The post Valeritas inks Israeli distro deal with Tritech Biomed appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 28, 2019 Category: Medical Devices Authors: Fink Densford Tags: Diabetes Distribution Drug-Device Combinations Featured Valeritas Source Type: news

DarioHealth, Glytec ink joint marketing deal
DarioHealth (NSDQ:DRIO) said today it inked a joint marketing agreement with Glytec through which DarioHealth’s smart glucose meter will be able to transmit information to Glytec’s Glucommander Outpatient software. Israel-based DarioHealth said that blood glucose data from its Dario Blood Glucose Monitoring System will now be imported into the Glucommander Outpatient for use in conjunction with other clinical data to create personalized insulin dose recommendations. Read the whole story on our sister site, Drug Delivery Business News The post DarioHealth, Glytec ink joint marketing deal appeared first on M...
Source: Mass Device - March 27, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Diabetes Featured DarioHealth Corp Glytec Source Type: news